{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:37:21Z","timestamp":1791405441869,"version":"4.3.3"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000102","name":"Health Resources and Services Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Sickle cell disease (SCD) is an inherited blood disorder that affects about 100,000 people in the U.S., primarily Blacks\/African-Americans. A multitude of complications negatively impacts quality of life. Hydroxyurea has been FDA approved since 1998 as a disease-modifying therapy for SCD, but is underutilized. Negative and uninformed perceptions of hydroxyurea and barriers to its use hinder adherence and promotion of the medication. As the largest real-world study to date that assessed hydroxyurea use for children and adults with SCD, we gathered and analyzed perspectives of providers, individuals with SCD, and families. Participants provided information about socio-demographics, hospital and emergency admissions for pain, number of severe pain episodes interfering with daily activities, medication adherence, and barriers to hydroxyurea. Providers reported on indications for hydroxyurea, reasons not prescribed, and current laboratory values. We found that hydroxyurea use was reported in over half of eligible patients from this large geographic region in the U.S., representing a range of sickle cell specialty clinical settings and practices. Provider and patient\/caregiver reports about hydroxyurea use were consistent with one another; adults 26\u00a0years and older were least likely to be on hydroxyurea; and the likelihood of being on hydroxyurea decreased with one or more barriers. Using the intentional and unintentional medication nonadherence framework, we found that, even for patients on hydroxyurea, challenges to taking the medicine at the right time and forgetting were crucial unintentional barriers to adherence. Intentional barriers such as worry about side effects and \u201ctried and it did not work\u201d were important barriers for young adults and adults. For providers, diagnoses other than HgbSS or HgbS-\u03b20 thalassemia were associated with lower odds of prescribing, consistent with evidence-based guidelines. Our results support strengthening provider understanding and confidence in implementing existing SCD guidelines, and the importance of shared decision making. Our findings can assist providers in understanding choices and decisions of families; guide individualized clinical discussions regarding hydroxyurea therapy; and help with developing tailored interventions to address barriers. Addressing barriers to hydroxyurea use can inform strategies to minimize similar barriers in the use of emerging and combination therapies for SCD.<\/jats:p>","DOI":"10.3389\/fgene.2022.921432","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T12:18:20Z","timestamp":1661516300000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative"],"prefix":"10.3389","volume":"13","author":[{"given":"Marsha J.","family":"Treadwell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Wun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha E.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Crook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong H.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Camilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Cavazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Nugent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/ajh.23547","article-title":"Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWiTCH clinical trial","volume":"88","author":"Alvarez","year":"2013","journal-title":"Am. J. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/pbc.25503","article-title":"Health related quality of life and perception of stigmatisation in adolescents living with sickle cell disease in Nigeria: A cross sectional study","volume":"62","author":"Adeyemo","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood.V124.21.560.560","article-title":"Long-term safety of hydroxyurea in sickle cell anemia and other benign diseases: Systematic review and meta-analysis","volume":"124","author":"Algiraigri","year":"2014","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(05)78941-8","article-title":"US FDA approves first drug for sickle-cell anaemia","volume":"351","author":"Ault","year":"1998","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/pbc.25905","article-title":"Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease","volume":"63","author":"Badawy","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ejh.12878","article-title":"Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease","volume":"98","author":"Badawy","year":"2017","journal-title":"Eur. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"949535","DOI":"10.1100\/2012\/949535","article-title":"Beyond the definitions of the phenotypic complications of sickle cell disease: An update on management","volume":"2012","author":"Ballas","year":"2012","journal-title":"ScientificWorldJournal."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2011.34.7542","article-title":"Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms","volume":"29","author":"Bj\u00f6rkholm","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2333794X19847026","DOI":"10.1177\/2333794X19847026","article-title":"Barriers to pediatric sickle cell disease guideline recommendations","volume":"6","author":"Cabana","year":"2019","journal-title":"Glob. Pediatr. Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/bjh.13093","article-title":"Hydroxycarbamide treatment in sickle cell disease: Estimates of possible leukaemia risk and of hospitalization survival benefit","volume":"167","author":"Castro","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B12","volume-title":"Data & statistics on sickle cell disease | CDC [WWW document]. Cent. Dis. Control Prev","author":"Centers for Disease Control and Prenvention (Cdc)","year":"2020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/archdischild-2013-303773","article-title":"Sickle cell disease: A neglected chronic disease of increasing global health importance","volume":"100","author":"Chakravorty","year":"2015","journal-title":"Arch. Dis. Child."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1002\/pbc.24931","article-title":"A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease","volume":"61","author":"Creary","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MPH.0000000000001257","article-title":"Development of a hydroxyurea decision aid for parents of children with sickle cell anemia","volume":"41","author":"Crosby","year":"2019","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e8130","DOI":"10.2196\/mhealth.8130","article-title":"A medication adherence app for children with sickle cell disease: Qualitative study","volume":"7","author":"Curtis","year":"2019","journal-title":"JMIR MHealth UHealth"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/bloodadvances.2018021444","article-title":"Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial)","volume":"2","author":"Daak","year":"2018","journal-title":"Blood Adv."},{"key":"B19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1401731","article-title":"Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia","volume":"371","author":"DeBaun","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1182\/bloodadvances.2017010702","article-title":"Standard measures for sickle cell disease research: The PhenX Toolkit sickle cell disease collections","volume":"1","author":"Eckman","year":"2017","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1002\/pbc.25177","article-title":"Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia","volume":"61","author":"Estepp","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3109\/03630269.2011.626098","article-title":"Neurocognitive testing and functioning in adults sickle cell disease","volume":"35","author":"Feliu","year":"2011","journal-title":"Hemoglobin"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e0171067","DOI":"10.1371\/journal.pone.0171067","article-title":"NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease","volume":"12","author":"Field","year":"","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/bloodadvances.2017009613","article-title":"Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease","volume":"1","author":"Field","year":"","journal-title":"Blood Adv."},{"key":"B25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1182\/bloodadvances.2016002972","article-title":"Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT","volume":"1","author":"Fitzhugh","year":"2017","journal-title":"Blood Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e26689","DOI":"10.1002\/pbc.26689","article-title":"Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study","volume":"64","author":"Green","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ajh.21883","article-title":"Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease","volume":"86","author":"Haywood","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/bloodadvances.2020001701","article-title":"Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: A qualitative study","volume":"4","author":"Hodges","year":"2020","journal-title":"Blood Adv."},{"key":"B29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: A pilot efficacy trial","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1182\/blood-2018-08-868893","article-title":"A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease","volume":"133","author":"Howard","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/ajh.25273","article-title":"A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study","volume":"93","author":"Hsu","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s12185-016-2027-x","article-title":"Adherence to hydroxyurea medication by children with sickle cell disease (SCD) using an electronic device: A feasibility study","volume":"104","author":"Inoue","year":"2016","journal-title":"Int. J. Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/ajh.21873","article-title":"Pain management in children and adolescents with sickle cell disease","volume":"86","author":"Jerrell","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"327","DOI":"10.5001\/omj.2019.64","article-title":"Hydroxyurea: Pattern of use, patient Adherence, and safety profile in patients with sickle cell disease in Oman","volume":"34","author":"Jose","year":"2019","journal-title":"Oman Med. J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/bloodadvances.2020001743","article-title":"Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects","volume":"4","author":"Kanter","year":"2020","journal-title":"Blood Adv."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/1097-0142(197204)29:4<1052::AID-CNCR2820290454>3.0.CO","article-title":"Hydroxyurea therapy in chronic myelogenous leukemia","volume":"29","author":"Kennedy","year":"1972","journal-title":"Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"217047","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: An overview","volume":"2015","author":"Lam","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JBM.S97405","article-title":"Hydroxyurea decreases hospitalizations in pediatric patients with Hb SC and Hb SB+ thalassemia","volume":"6","author":"Lebensburger","year":"2015","journal-title":"J. Blood Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MPH.0000000000000743","article-title":"Utilizing a novel mobile health \u201cselfie\u201d application to improve compliance to iron chelation in pediatric patients receiving chronic transfusions","volume":"39","author":"Leonard","year":"2017","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/bjh.12323","article-title":"The effect of hydroxcarbamide therapy on survival of children with sickle cell disease","volume":"161","author":"Lobo","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ajh.24255","article-title":"Effects of hydroxyurea treatment for patients with hemoglobin SC disease","volume":"91","author":"Luchtman-Jones","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12874-016-0245-9","article-title":"Rationale and design of mDOT-HuA study: A randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania","volume":"16","author":"Makubi","year":"2016","journal-title":"BMC Med. Res. Methodol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1080\/09602011.2019.1598876","article-title":"Neurocognitive functioning in symptomatic adults with sickle cell disease: A description and comparison with unaffected siblings","volume":"30","author":"Martin","year":"2020","journal-title":"Neuropsychol. Rehabil."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1002382","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med."},{"key":"B47","volume-title":"Evidence-based management of sickle cell disease: Expert panel report","year":"2014"},{"key":"B48","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"Investigators of the phase 3 trial of l-glutamine in sickle cell DiseaseA phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"765958","DOI":"10.3389\/fgene.2021.765958","article-title":"Barriers to therapeutic use of hydroxyurea for sickle cell disease in Nigeria: A cross-sectional survey","volume":"12","author":"Okocha","year":"2022","journal-title":"Front. Genet."},{"key":"B50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/pbc.24381","article-title":"Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease","volume":"60","author":"Oyeku","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jpeds.2018.05.019","article-title":"Targeted hydroxyurea education after an emergency department visit increases hydroxyurea use in children with sickle cell anemia","volume":"201","author":"Pecker","year":"2018","journal-title":"J. Pediatr."},{"key":"B52","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4338\/ACI-2016-12-RA-0203","article-title":"Improving medication adherence with two-way short message service reminders in sickle cell disease and asthma. A feasibility randomized controlled trial","volume":"8","author":"Pernell","year":"2017","journal-title":"Appl. Clin. Inf."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle cell disease","volume":"376","author":"Piel","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e28006","DOI":"10.1002\/pbc.28006","article-title":"Universal screening for social determinants of health in pediatric sickle cell disease: A quality-improvement initiative","volume":"67","author":"Power-Hays","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/MOH.0000000000000582","article-title":"Effective use of hydroxyurea for sickle cell anemia in low-resource countries","volume":"27","author":"Power-Hays","year":"2020","journal-title":"Curr. Opin. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1093\/jpepsy\/jsz031","article-title":"Cognitive function in sickle cell disease across domains, cerebral infarct status, and the lifespan: A meta-analysis","volume":"44","author":"Prussien","year":"2019","journal-title":"J. Pediatr. Psychol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2018-03-834440","article-title":"l-Glutamine for sickle cell anemia: more questions than answers","volume":"132","author":"Quinn","year":"2018","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.bcmd.2017.08.017","article-title":"Italian multicenter study of hydroxyurea in sickle cell anemia InvestigatorsReal-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent","volume":"69","author":"Rigano","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"e0199375","DOI":"10.1371\/journal.pone.0199375","article-title":"From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea","volume":"13","author":"Sinha","year":"2018","journal-title":"PLOS ONE"},{"key":"B60","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jnma.2018.09.004","article-title":"Improving uptake of hydroxyurea in patients with sickle cell disease: A retrospective study of a clinic-based change in consenting practices","volume":"111","author":"Smith","year":"2019","journal-title":"J. Natl. Med. Assoc."},{"key":"B61","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"Investigators of the multicenter study of hydroxyurea in sickle cell anemia and msh patients\u2019 follow-UpThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am. J. Hematol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","article-title":"Self-report measures of medication adherence behavior: Recommendations on optimal use","volume":"5","author":"Stirratt","year":"2015","journal-title":"Transl. Behav. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1553-2712.2012.01330.x","article-title":"Adult emergency department patients with sickle cell pain crisis: Results from a quality improvement learning collaborative model to improve analgesic management","volume":"19","author":"Tanabe","year":"2012","journal-title":"Acad. Emerg. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in sub-saharan africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/pbc.24283","article-title":"Hydroxyurea treatment of children with hemoglobin SC disease","volume":"60","author":"Yates","year":"2013","journal-title":"Pediatr. Blood Cancer"}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.921432\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T12:18:29Z","timestamp":1661516309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2022.921432\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":68,"alternative-id":["10.3389\/fgene.2022.921432"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2022.921432","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,26]]},"article-number":"921432"}}